GlassScriptPhysician profile
Bradley Alan Bertram
NPI 1184785008
$15,564.52
in general payments reported to CMS, 2019-2025
36 companies · $44.40 in 2025
The $44.40 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,907 · 2020: $681 · 2021: $7,396 · 2022: $2,045 · 2023: $1,993 · 2024: $1,499 · 2025: $44.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,536.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akorn Operating Company LLC | $5,000.00 | 2021 | |
| Alcon Vision LLC | $2,942.93 | 2019-2025 | Clareon, Argos, Hydrus Microstent |
| Sun Pharmaceutical Industries INC. | $1,223.89 | 2019-2024 | Cequa |
| Glaukos Corporation | $1,044.63 | 2019-2024 | Idose, Istent Inject Trabecular Micro-Bypass System, Iaccess Precision Blade |
| Allergan, INC. | $590.64 | 2019-2022 | |
| Ivantis, INC | $531.82 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $505.00 | 2019-2021 | |
| New World Medical,INC. | $463.84 | 2022-2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Mallinckrodt Hospital Products INC. | $389.53 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $373.13 | 2022-2024 | Miebo, Vyzulta, Xiidra |
| Novartis Pharmaceuticals Corporation | $358.53 | 2019-2023 | |
| Abbvie INC. | $251.71 | 2022-2024 | Durysta, Lumigan |
| Johnson & Johnson Surgical Vision, INC. | $236.62 | 2022-2023 | Tecnis Iol, Tecnis Simplicity, Catalys System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $210.75 | 2019-2021 | |
| Oyster Point Pharma, INC. | $196.28 | 2022-2024 | Tyrvaya |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $154.11 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $137.22 | 2019 | |
| Harrow Eye, LLC | $127.57 | 2024 | Iheezo |
| Biotissue Holdings INC. | $108.30 | 2019-2021 | |
| Genentech, INC. | $104.72 | 2022 | |
| Sight Sciences, INC. | $102.36 | 2019-2024 | Omni Surgical System |
| Tarsus Pharmaceuticals, INC. | $88.37 | 2024 | Xdemvy |
| Shire North American Group INC | $84.54 | 2019 | |
| Dompe US, INC. | $61.26 | 2019-2024 | Oxervate |
| Ocular Therapeutix, INC. | $40.04 | 2019-2022 | |
| Carl Zeiss Meditec USA, INC. | $33.06 | 2023 | Clarus |
| Iridex Corporation | $29.55 | 2019 | |
| Omeros Corporation | $25.23 | 2019 | |
| Carl Zeiss Meditec, INC. | $22.22 | 2019 | |
| Amgen INC. | $20.62 | 2024 | Tepezza |
| Eyepoint US, INC. | $20.30 | 2019 | |
| Thea Pharma INC. | $18.18 | 2023 | |
| Quidel Corporation | $18.07 | 2023 | |
| Rxsight INC | $17.47 | 2022 | |
| Aerie Pharmaceuticals, INC. | $17.06 | 2019 | |
| Horizon Therapeutics Plc | $14.97 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Bertram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.